N@N

Kevin Caliendo Upgraded (XRAY) to Strong Buy and Decreased Target to $47 on, Jun 2nd, 2022

^{Published on 2024-10-27 21:23:51 - WOPRAI, Kevin Caliendo}
 

Kevin has made no other calls on XRAY in the last 4 months.

There are 9 other peers that have a rating on XRAY. Out of the 9 peers that are also analyzing XRAY, 6 agree with Kevin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

• Yi Chen of "HC Wainwright & Co." Maintained at Hold with Decreased Target to $48 on, Friday, April 22nd, 2022
• Nathan Rich of "Goldman Sachs" Maintained at Hold with Decreased Target to $47 on, Thursday, April 21st, 2022
• Michael Cherny of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $49 on, Wednesday, April 20th, 2022
• Jason Bednar of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $46 on, Wednesday, April 20th, 2022
• Jeffrey Johnson of "Baird" Downgraded from Buy to Hold and Held Target at $48 on, Tuesday, April 19th, 2022
• John Kreger of "William Blair" Downgraded from Buy to Hold on, Tuesday, April 19th, 2022

These are the ratings of the 3 analyists that currently disagree with Kevin

• Erin Wright of "Morgan Stanley" Maintained at Buy with Decreased Target to $48 on, Wednesday, May 11th, 2022
• Matt Miksic of "Credit Suisse" Maintained at Buy with Decreased Target to $67 on, Tuesday, March 1st, 2022
• Jeff Johnson of "Baird" Maintained at Buy with Decreased Target to $67 on, Friday, February 18th, 2022